Lexicon Pharmaceuticals Inc (LXRX) - Net Assets
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has net assets worth $107.54 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($184.99 Million) and total liabilities ($77.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lexicon Pharmaceuticals Inc (LXRX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $107.54 Million |
| % of Total Assets | 58.13% |
| Annual Growth Rate | 10.4% |
| 5-Year Change | -5.33% |
| 10-Year Change | -31.68% |
| Growth Volatility | 481.21 |
Lexicon Pharmaceuticals Inc - Net Assets Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore LXRX total assets for the complete picture of this company's asset base.
Annual Net Assets for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual net assets of Lexicon Pharmaceuticals Inc from 1999 to 2025. For live valuation and market cap data, see Lexicon Pharmaceuticals Inc (LXRX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $107.54 Million | -26.32% |
| 2024-12-31 | $145.95 Million | +56.75% |
| 2023-12-31 | $93.11 Million | -20.50% |
| 2022-12-31 | $117.12 Million | +3.11% |
| 2021-12-31 | $113.59 Million | -27.36% |
| 2020-12-31 | $156.37 Million | +33.54% |
| 2019-12-31 | $117.10 Million | +543.48% |
| 2018-12-31 | $-26.41 Million | -150.68% |
| 2017-12-31 | $52.10 Million | -66.90% |
| 2016-12-31 | $157.40 Million | -44.94% |
| 2015-12-31 | $285.85 Million | +0.65% |
| 2014-12-31 | $284.02 Million | +66.91% |
| 2013-12-31 | $170.16 Million | -36.19% |
| 2012-12-31 | $266.68 Million | -10.38% |
| 2011-12-31 | $297.57 Million | +20.46% |
| 2010-12-31 | $247.02 Million | +51.09% |
| 2009-12-31 | $163.50 Million | -16.51% |
| 2008-12-31 | $195.83 Million | -31.67% |
| 2007-12-31 | $286.57 Million | +235.17% |
| 2006-12-31 | $85.50 Million | -0.35% |
| 2005-12-31 | $85.80 Million | -29.44% |
| 2004-12-31 | $121.59 Million | -26.85% |
| 2003-12-31 | $166.22 Million | -2.17% |
| 2002-12-31 | $169.90 Million | -22.20% |
| 2001-12-31 | $218.37 Million | +5.17% |
| 2000-12-31 | $207.63 Million | +2432.05% |
| 1999-12-31 | $8.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lexicon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 198868300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $366.00K | 0.34% |
| Other Comprehensive Income | $30.00K | 0.03% |
| Other Components | $2.12 Billion | 1975.79% |
| Total Equity | $107.54 Million | 100.00% |
Lexicon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Independent Bank Corporation
NASDAQ:IBCP
|
$690.65 Million |
|
Shenzhen Bestek Technology Co Ltd
SHE:300822
|
$690.65 Million |
|
Guangzhou Haoyang Electronic Co Ltd
SHE:300833
|
$690.78 Million |
|
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
|
$691.28 Million |
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
$690.51 Million |
|
Shenzhen Expressway Company Limited
F:SHZH
|
$690.39 Million |
|
Shanghai CEO Environmental Protection Technology Co Ltd
SHG:688335
|
$690.37 Million |
|
IPH Ltd
AU:IPH
|
$690.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lexicon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 145,950,000 to 107,538,000, a change of -38,412,000 (-26.3%).
- Net loss of 50,341,000 reduced equity.
- Share repurchases of 572,000 reduced equity.
- Other comprehensive income decreased equity by 89,000.
- Other factors increased equity by 12,590,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.34 Million | -46.81% |
| Share Repurchases | $572.00K | -0.53% |
| Other Comprehensive Income | $-89.00K | -0.08% |
| Other Changes | $12.59 Million | +11.71% |
| Total Change | $- | -26.32% |
Book Value vs Market Value Analysis
This analysis compares Lexicon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.70x to 5.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $2.34 | $1.63 | x |
| 2000-12-31 | $34.92 | $1.63 | x |
| 2001-12-31 | $30.44 | $1.63 | x |
| 2002-12-31 | $22.76 | $1.63 | x |
| 2003-12-31 | $20.48 | $1.63 | x |
| 2004-12-31 | $13.44 | $1.63 | x |
| 2005-12-31 | $9.39 | $1.63 | x |
| 2006-12-31 | $8.95 | $1.63 | x |
| 2007-12-31 | $17.98 | $1.63 | x |
| 2008-12-31 | $9.50 | $1.63 | x |
| 2009-12-31 | $7.88 | $1.63 | x |
| 2010-12-31 | $5.71 | $1.63 | x |
| 2011-12-31 | $6.11 | $1.63 | x |
| 2012-12-31 | $3.81 | $1.63 | x |
| 2013-12-31 | $-13.70 | $1.63 | x |
| 2014-12-31 | $3.72 | $1.63 | x |
| 2015-12-31 | $2.76 | $1.63 | x |
| 2016-12-31 | $1.52 | $1.63 | x |
| 2017-12-31 | $0.50 | $1.63 | x |
| 2018-12-31 | $-13.91 | $1.63 | x |
| 2019-12-31 | $1.00 | $1.63 | x |
| 2020-12-31 | $1.41 | $1.63 | x |
| 2021-12-31 | $0.78 | $1.63 | x |
| 2022-12-31 | $0.71 | $1.63 | x |
| 2023-12-31 | $0.42 | $1.63 | x |
| 2024-12-31 | $0.46 | $1.63 | x |
| 2025-12-31 | $0.30 | $1.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lexicon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -101.08%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.72x
- Recent ROE (-46.81%) is above the historical average (-54.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -152.44% | -265.96% | 0.21x | 2.72x | $-13.32 Million |
| 2000 | -12.52% | -179.78% | 0.07x | 1.06x | $-46.76 Million |
| 2001 | -16.11% | -11.51% | 1.27x | 1.10x | $-57.01 Million |
| 2002 | -35.12% | -169.52% | 0.17x | 1.19x | $-76.66 Million |
| 2003 | -38.62% | -149.86% | 0.15x | 1.71x | $-80.82 Million |
| 2004 | -38.79% | -76.40% | 0.29x | 1.74x | $-59.33 Million |
| 2005 | -42.32% | -47.98% | 0.35x | 2.55x | $-44.90 Million |
| 2006 | -63.52% | -74.61% | 0.38x | 2.23x | $-62.86 Million |
| 2007 | -22.94% | -117.31% | 0.14x | 1.44x | $-84.42 Million |
| 2008 | -41.42% | -237.80% | 0.12x | 1.41x | $-95.42 Million |
| 2009 | -50.54% | -773.64% | 0.04x | 1.57x | $-99.16 Million |
| 2010 | -41.20% | -2073.66% | 0.01x | 1.49x | $-126.48 Million |
| 2011 | -39.05% | -6285.29% | 0.00x | 1.45x | $-145.97 Million |
| 2012 | -41.33% | -10120.39% | 0.00x | 1.39x | $-136.88 Million |
| 2013 | 0.00% | -4686.14% | 0.01x | 0.00x | $-3.73 Million |
| 2014 | -35.31% | -438.85% | 0.05x | 1.66x | $-128.70 Million |
| 2015 | -1.64% | -3.60% | 0.20x | 2.29x | $-33.27 Million |
| 2016 | -89.85% | -169.71% | 0.18x | 3.02x | $-157.17 Million |
| 2017 | -247.69% | -142.86% | 0.21x | 8.38x | $-134.26 Million |
| 2018 | 0.00% | -190.71% | 0.22x | 0.00x | $26.61 Million |
| 2019 | 111.13% | 40.40% | 0.77x | 3.57x | $118.42 Million |
| 2020 | -37.46% | -244.11% | 0.12x | 1.30x | $-74.21 Million |
| 2021 | -77.26% | -29448.99% | 0.00x | 1.21x | $-99.12 Million |
| 2022 | -87.04% | -73341.01% | 0.00x | 1.66x | $-113.66 Million |
| 2023 | -190.23% | -14710.88% | 0.01x | 2.46x | $-186.43 Million |
| 2024 | -137.31% | -644.78% | 0.10x | 2.04x | $-215.00 Million |
| 2025 | -46.81% | -101.08% | 0.27x | 1.72x | $-61.09 Million |
Industry Comparison
This section compares Lexicon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc (LXRX) | $107.54 Million | -152.44% | 0.72x | $690.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more